https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr 3095)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr 3095)2014-06-01 00:00:002014-06-01 00:00:00Combined chemoimmunotherapy of castrate-resistant prostate cancer with dendritic-cell based vaccine DCVAC/Pca.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr 3099)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr 3099)2014-06-01 00:00:002014-06-01 00:00:00Cancer immunotherapy of patients with the biochemical relapse of the prostate cancer using dendritic cell-based vaccine DCVAC/PCa.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr 3062)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr 3062)2014-06-01 00:00:002014-06-01 00:00:00γδ T cells in combination with Newcastle disease virus and dendritic cell therapy as a novel immunotherapeutic approach in treating of advanced lung cancer.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr TPS3134)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr TPS3134)2014-06-01 00:00:002014-06-01 00:00:00Autologous dendritic cell vaccination (DCVAC/OvCa) added to standard of care therapy in three open-label randomized phase 2 studies in women with advanced stage ovarian cancer (OC).
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-06-01 / Lancet Oncol. 2014 Jun;15(7):e257-67
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-06-01 / Lancet Oncol. 2014 Jun;15(7):e257-672014-06-01 00:00:002019-02-15 08:35:59Clinical use of dendritic cells for cancer therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr 3085)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr 3085)2014-06-01 00:00:002021-08-09 07:54:01Intratumoral vaccination with activated allogeneic dendritic cells in patients with newly diganosed metastatic renal cell carcinoma (mRCC).
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-05-31 / J Clin Oncol 32:5s, 2014 (suppl; abstr 2087)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-05-31 / J Clin Oncol 32:5s, 2014 (suppl; abstr 2087)2014-05-31 11:58:292019-07-17 11:58:59Association of increased progression-free survival in primary glioblastomas with lymphopenia at baseline and activation of NK and NKT cells after dendritic cell immunotherapy.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-05-31 / J Clin Oncol 32:5s, 2014 (suppl; abstr 7583)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-05-31 / J Clin Oncol 32:5s, 2014 (suppl; abstr 7583)2014-05-31 00:00:002019-07-31 11:59:46Dendritic cell vaccination in malignant pleural mesothelioma: A phase I/II study.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-05-30 / J Clin Oncol 32, 2014 (suppl; abstr e15254)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-05-30 / J Clin Oncol 32, 2014 (suppl; abstr e15254)2014-05-30 00:00:002014-05-30 00:00:00A feasibility and safety study of vaccination with poly-ICLC and peptide-pulsed dendritic cells in patients with metastatic, locally advanced unresectable, or recurrent pancreatic adenocarcinoma.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-05-21 / Expert Rev Anticancer Ther 2014 Jul;14(7):761-3
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-05-21 / Expert Rev Anticancer Ther 2014 Jul;14(7):761-32014-05-21 00:00:002019-02-15 08:46:21Dendritic cell immunotherapy for glioblastoma
